【制药网 行业动态】近年来,我国创新药利好政策频出,从研发到审评,再到生产与支付等各环节,政策环境持续优化。越来越多国内外,创新药开始在中国获批上市。据统计,今年上半年,我国创新药物审批领域共有43个创新药获得上市批准。而进入7月,又有大批药企又迎来了产品上市的喜讯。强生兰泽替尼获批上市7月30日,强生第三代EGFR抑制剂兰泽替尼在中国获批,联合EGFR/c-Met双抗埃万妥单抗,用于一线治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.